Delcath Presents Real-World Data on Liver-Directed Therapy for Metastatic Breast Cancer
Event summary
- Delcath Systems presented new data on percutaneous hepatic perfusion with melphalan (M-PHP) for liver-dominant metastatic breast cancer at ESMO Breast Cancer 2026.
- Retrospective analysis of 15 patients showed a 60% hepatic partial response rate and median overall survival of 6.0 months.
- HEPZATO KIT is currently being evaluated in a randomized Phase 2 trial (PHP-MBC-202) for metastatic breast cancer with liver-dominant disease.
- The study was conducted by independent investigators at three European centers.
The big picture
Delcath's presentation of real-world evidence for M-PHP in metastatic breast cancer highlights the growing interest in liver-directed therapies for difficult-to-treat cancers. The data comes as interventional oncology gains traction, with companies exploring targeted approaches to improve outcomes in metastatic disease. The Phase 2 trial underway could further validate the technology, but competition and reimbursement dynamics remain key hurdles.
What we're watching
- Clinical Validation
- Whether the real-world data will accelerate adoption of M-PHP in heavily pretreated breast cancer patients.
- Regulatory Pathway
- The pace at which Delcath advances its Phase 2 trial and potential expansion into new indications.
- Commercial Strategy
- How Delcath positions HEPZATO KIT in the competitive landscape of liver-directed therapies.
Related topics